As such and given the fact that incretin-based therapies were first introduced for T2D treatment in 2005, there is still no data regarding the true impact of these drugs in the risk for these types of tumors, since the effect present is probably too small to be detected. This evidence concerns the gene GCG and type 2 diabetes mellitus.